Literature DB >> 18591461

Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic.

Stephen T Turner1, Kent R Bailey, Brooke L Fridley, Arlene B Chapman, Gary L Schwartz, High Seng Chai, Hugues Sicotte, Jean-Pierre Kocher, Andréi S Rodin, Eric Boerwinkle.   

Abstract

We conducted a genome-wide association study to identify novel genes influencing diastolic blood pressure (BP) response to hydrochlorothiazide, a commonly prescribed thiazide diuretic preferred for the treatment of high BP. Affymetrix GeneChip Human Mapping 100K Arrays were used to measure single nucleotide polymorphisms across the 22 autosomes in 194 non-Hispanic black subjects and 195 non-Hispanic white subjects with essential hypertension selected from opposite tertiles of the race- and sex-specific distributions of age-adjusted diastolic BP response to hydrochlorothiazide (25 mg daily, PO, for 4 weeks). The black sample consisted of 97 "good" responders (diastolic BP response [mean+/-SD]=-18.3+/-4.2 mm Hg; age=47.1+/-6.1 years; 51.5% women) and 97 "poor" responders (diastolic BP response=-0.18+/-4.3; age=47.4+/-6.5 years; 51.5% women). Haplotype trend regression identified a region of chromosome 12q15 in which haplotypes constructed from 3 successive single nucleotide polymorphisms (rs317689, rs315135, and rs7297610) in proximity to lysozyme (LYZ), YEATS domain containing 4 (YEATS4), and fibroblast growth receptor substrate 2 (FRS2) were significantly associated with diastolic BP response (nominal P=2.39 x 10(-7); Bonferroni corrected P=0.024; simulated experiment-wise P=0.040). Genotyping of 35 additional single nucleotide polymorphisms selected to "tag" linkage disequilibrium blocks in these genes provided corroboration that variation in LYZ and YEATS4 was associated with diastolic BP response in a statistically independent data set of 291 black subjects and in the sample of 294 white subjects. These results support the use of genome-wide association analyses to identify novel genes influencing antihypertensive drug responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591461      PMCID: PMC2692710          DOI: 10.1161/HYPERTENSIONAHA.107.104273

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

1.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

2.  Whole-genome patterns of common DNA variation in three human populations.

Authors:  David A Hinds; Laura L Stuve; Geoffrey B Nilsen; Eran Halperin; Eleazar Eskin; Dennis G Ballinger; Kelly A Frazer; David R Cox
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic.

Authors:  Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Eric Boerwinkle
Journal:  Hypertension       Date:  2005-09-19       Impact factor: 10.190

Review 4.  Reliability of statistical associations between genes and disease.

Authors:  Kenneth F Manly
Journal:  Immunogenetics       Date:  2005-09-29       Impact factor: 2.846

5.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

Review 6.  Personalized medicine for high blood pressure.

Authors:  Stephen T Turner; Gary L Schwartz; Eric Boerwinkle
Journal:  Hypertension       Date:  2007-04-30       Impact factor: 10.190

7.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

8.  Detection and control of high blood pressure in the community : Do we need a wake-up call?

Authors:  I Meissner; J P Whisnant; S G Sheps; G L Schwartz; W M O'Fallon; J L Covalt; J D Sicks; K R Bailey; D O Wiebers
Journal:  Hypertension       Date:  1999-09       Impact factor: 10.190

9.  Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  R A Preston; B J Materson; D J Reda; D W Williams; R J Hamburger; W C Cushman; R J Anderson
Journal:  JAMA       Date:  1998-10-07       Impact factor: 56.272

10.  A transcriptional profile of aging in the human kidney.

Authors:  Graham E J Rodwell; Rebecca Sonu; Jacob M Zahn; James Lund; Julie Wilhelmy; Lingli Wang; Wenzhong Xiao; Michael Mindrinos; Emily Crane; Eran Segal; Bryan D Myers; James D Brooks; Ronald W Davis; John Higgins; Art B Owen; Stuart K Kim
Journal:  PLoS Biol       Date:  2004-11-30       Impact factor: 8.029

View more
  53 in total

Review 1.  Genome-wide association studies in pharmacogenomics.

Authors:  Ann K Daly
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

Review 2.  Pharmacogenomics of hypertension and heart disease.

Authors:  Meghan J Arwood; Larisa H Cavallari; Julio D Duarte
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

3.  Pharmacogenomics of antihypertensive drugs: past, present and future.

Authors:  Julie A Johnson
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

4.  A genomewide association study of citalopram response in major depressive disorder.

Authors:  Holly A Garriock; Jeffrey B Kraft; Stanley I Shyn; Eric J Peters; Jennifer S Yokoyama; Gregory D Jenkins; Megan S Reinalda; Susan L Slager; Patrick J McGrath; Steven P Hamilton
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

Review 5.  Personalized medicine: Genetic risk prediction of drug response.

Authors:  Ge Zhang; Daniel W Nebert
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

Review 6.  Genetics of hypertension and cardiovascular disease and their interconnected pathways: lessons from large studies.

Authors:  Aldi T Kraja; Steven C Hunt; D C Rao; Victor G Dávila-Román; Donna K Arnett; Michael A Province
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 7.  Data-driven methods to discover molecular determinants of serious adverse drug events.

Authors:  A P Chiang; A J Butte
Journal:  Clin Pharmacol Ther       Date:  2009-01-28       Impact factor: 6.875

8.  Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.

Authors:  Kimberly S Collins; Victoria M Pratt; Wesley M Stansberry; Elizabeth B Medeiros; Karthik Kannegolla; Marelize Swart; Todd C Skaar; Arlene B Chapman; Brian S Decker; Ranjani N Moorthi; Michael T Eadon
Journal:  Pharmacogenet Genomics       Date:  2019-01       Impact factor: 2.089

Review 9.  Hypertension pharmacogenomics: in search of personalized treatment approaches.

Authors:  Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

10.  GLOSSI: a method to assess the association of genetic loci-sets with complex diseases.

Authors:  High-Seng Chai; Hugues Sicotte; Kent R Bailey; Stephen T Turner; Yan W Asmann; Jean-Pierre A Kocher
Journal:  BMC Bioinformatics       Date:  2009-04-03       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.